Sanofi successfully prices EUR 8 billion of bond issues
15 Março 2018 - 3:01AM
|
Press ReleaseSource: Sanofi (EURONEXT: SAN)
(NYSE: SNY) |
Sanofi
successfully prices EUR 8 billion of bond issues Paris,
France - March 15, 2018 - Sanofi has successfully priced its
offering of EUR 8 billion of notes (the "Notes") across 6
tranches: €1.0 billion floating rate notes, due March 2020, bearing
interest at a quarterly rate of 3-month EURIBOR + 15 bp €0.5
billion fixed rate notes, due March 2020, bearing interest at an
annual rate of 0.0% €1.75 billion fixed rate notes, due March 2023,
bearing interest at an annual rate of 0.5% €1.5 billion fixed rate
notes, due March 2026, bearing interest at an annual rate of 1.0%
€2.0 billion fixed rate notes, due March 2030, bearing interest at
an annual rate of 1.375% €1.25 billion fixed rate notes, due March
2038, bearing interest at an annual rate of 1.875% The issues are
made under the company's Euro Medium Term Note Programme. The
transaction enables the company to lower its average cost of debt
and extend the average maturity of its debt. Sanofi intends to use
the net proceeds of the offering for general corporate purposes,
including the financing of the acquisitions of Bioverativ and
Ablynx. BNP Paribas, Société Générale CIB and UniCredit Bank acted
as Global Coordinators and Bookrunners, alongside Crédit Agricole
CIB, Citi, HSBC, ING, J.P. Morgan, RBC Capital Markets and
Santander which acted as Bookrunners for the offering. |
About Sanofi Sanofi is dedicated to supporting
people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic conditions. With
more than 100,000 people in 100 countries, Sanofi is transforming
scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life |
Media Relations Contact Laurence Bollack Tel.:
+33 (0)1 53 77 46 46 mr@sanofi.com |
Investor Relations
Contact George Grofik Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com |
DISCLAIMER This communication shall not
constitute an offer to sell or the solicitation of an offer to buy
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. The Notes have
not been and will not be registered under the Securities Act and
may not be offered or sold within the United States or to, or for
the account or benefit of, U.S. persons except in certain
transactions exempt from the registration requirements of the
Securities Act. PROHIBITION OF SALES TO EEA RETAIL INVESTORS - The
Notes are not intended to be offered, sold or otherwise made
available to and should not be offered, sold or otherwise made
available to any Retail Investor in the European Economic Area
("EEA"). For these purposes, a "Retail Investor" means a person who
is one (or more) of: (i) a retail client as defined in point (11)
of Article 4(1) of Directive 2014/65/EU ("MiFID II"); or (ii) a
customer within the meaning of Directive 2002/92/EC ("IMD"), where
that customer would not qualify as a professional client as defined
in point (10) of Article 4(1) of MiFID II. Consequently no key
information document required by Regulation (EU) No 1286/2014 (the
"PRIIPs Regulation") for offering or selling the Notes or otherwise
making them available to retail investors in the EEA has been or
will be prepared and therefore offering or selling the Notes or
otherwise making them available to any retail investor in the EEA
may be unlawful under the PRIIPS Regulation. This communication is
only being distributed to and is only directed at (i) persons who
are outside the United Kingdom or (ii) investment professionals
falling within Article 19(5) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii)
high net worth companies, and other persons to whom it may lawfully
be communicated, falling within Article 49(2)(a) to (d) of the
Order or (iv) persons to whom an invitation or inducement to engage
in investment activity (within the meaning of section 21 of the
Financial Services and Markets Act 2000) may otherwise lawfully be
communicated or cause to be communicated (all such persons together
being referred to as "relevant persons"). The Notes are only
available to, and any invitation, offer or agreement to subscribe,
purchase or otherwise acquire such Notes will be engaged in only
with, relevant persons. Any person who is not a relevant person
should not act or rely on this document or any of its contents. No
Notes have been offered or sold nor will be offered or sold,
directly or indirectly, to the public in France; the Base
Prospectus or any other offering material relating to the Notes
have not been distributed or caused to be distributed and will not
be distributed or caused to be distributed to the public in France;
such offers, sales and distributions have been and shall only be
made in France to persons licensed to provide the investment
service of portfolio management for the account of third parties or
to qualified investors (investisseurs qualifiés) other than
individuals, investing for their own account, all as defined in
Articles L. 411-1, L. 411-2 and D. 411-1 of the French Code
monétaire et financier. Forward-Looking StatementsAny
statements made in this communication that are not statements of
historical fact, including statements about Sanofi's beliefs and
expectations are forward-looking statements and should be evaluated
as such. Forward-looking statements include statements that may
relate to Sanofi's plans, objectives, strategies, goals, future
events, future revenues or performance, and other information that
is not historical information. Sanofi does not undertake, and
specifically disclaims, any obligation or responsibility to update
or amend any of the information above except as otherwise required
by law. Additional Information:This communication is neither
an offer to purchase nor a solicitation of any offer to sell any
securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. |
Attachment:
http://www.globenewswire.com/NewsRoom/AttachmentNg/6d231e8e-ca69-4ef2-96bb-301f6276e8de
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024